Free gift on orders $400+ · pick BPC-157, NAD+ 500MG, MOTS-C 10MG & more•Complimentary 2-day shipping over $250• Same-day dispatch before 12 PM MT• New batches made in the USA• ≥99% average purity · independent U.S. lab testing• Free gift on orders $400+ · pick BPC-157, NAD+ 500MG, MOTS-C 10MG & more•Complimentary 2-day shipping over $250• Same-day dispatch before 12 PM MT• New batches made in the USA• ≥99% average purity · independent U.S. lab testing•
0
Trust built by transparency. Scan the vial, read the lab’s own report.

Research overview

What Is DSIP?

Updated Nov 1, 20265 min readResearch use only
Research overview4 min readUpdated Nov 1, 2026

Delta sleep-inducing peptide (DSIP) is a nine-residue peptide that a Swiss research group isolated in the 1970s and named after changes in slow-wave, or delta, EEG activity in rabbits. Half a century later it remains one of the odder molecules in neuropeptide research: it has been reported to act in many systems, yet no gene, precursor protein or dedicated receptor for it has ever been found.

That gap is the main reason DSIP still draws attention. This article goes through its discovery, the structural and stability work, the neuroendocrine, mitochondrial and EEG studies that make up most of the literature, and the reasons reviewers describe the field as unresolved.

DSIP is currently out of stock at Rogue Compounds while the next batch is tested. View DSIP →

At a glance

  • Class: Linear nonapeptide; endogenous gene and receptor unidentified
  • Origin: Isolated from rabbit cerebral venous blood by Monnier, Schoenenberger and colleagues in Switzerland in the 1970s
  • Structure: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; C35H48N10O15; MW 848.8 g/mol; CAS 62568-57-4
  • Main research areas: EEG and sleep architecture in animals, pituitary and pineal regulation, mitochondrial respiration under hypoxia, glutamate receptor interactions, peptide stability
  • Regulatory status: Research chemical, not for human use

Structure and origin

The discovery came from a classic transfer experiment. Researchers in Basel electrically stimulated the thalamus of rabbits at low frequency to produce sleep-like EEG patterns, collected cerebral venous blood, and looked for a factor that could transfer those patterns to recipient animals. The active material was purified, sequenced as a nonapeptide, and then synthesized. Monnier and colleagues compared the original isolate with the synthetic peptide and reported similar properties in their rabbit preparations (Monnier et al., 1977).

The sequence is short, linear and rich in small residues: five of its nine amino acids are glycine or alanine, with an N-terminal tryptophan and acidic residues at positions 5 and 9. It carries no disulfide bond and no C-terminal amide. DSIP-like immunoreactivity was later reported in the brain, pituitary and several peripheral tissues, and in plasma. Yet searches of the genome have not found a gene encoding the peptide, and no specific high-affinity receptor has been cloned. Reviewers have proposed that DSIP may be a fragment of a larger, still unknown protein, or that the immunoreactive material differs from the synthetic sequence (Kovalzon & Strekalova, 2006).

Mechanism: what the research shows

Without a receptor, mechanism studies have relied on pharmacological interactions in tissue preparations. In rat pineal glands, Graf and Schoenenberger found that DSIP modulated the stimulation of N-acetyltransferase, the enzyme that controls melatonin synthesis, and that this effect involved the α1-adrenergic receptor (Graf & Schoenenberger, 1987). Other groups reported DSIP effects on release of luteinizing hormone, corticotropin and growth hormone in rats, and electrophysiology work suggested that some neuronal responses depended on NMDA-type glutamate receptors.

A separate line of work looked at energy metabolism. Using isolated rat brain mitochondria, Khvatova and colleagues measured respiration and oxidative phosphorylation in the presence of DSIP and examined its effect in an experimental hypoxia model (Khvatova et al., 2003). These studies suggest the peptide may act at several points, but they do not identify a primary target.

Key areas of study

EEG and sleep architecture in animals

The original studies measured EEG in rabbits, and later work extended this to rats and cats. Results varied: some laboratories reported increases in slow-wave or paradoxical sleep, others found little or no effect, and timing, route and species all seemed to matter. A 1988 review framed DSIP as a tool for investigating mechanisms of sleep onset rather than as an established sleep factor (Yehuda & Carasso, 1988).

Neuroendocrine regulation

The pineal N-acetyltransferase study is one of the more mechanistically specific DSIP papers, linking the peptide to adrenergic control of melatonin synthesis in rat tissue (Graf & Schoenenberger, 1987). Pituitary hormone studies in rats add to this picture, though their findings were not consistent across laboratories (Kovalzon & Strekalova, 2006).

Mitochondria and hypoxia

Mitochondrial respiration assays and hypoxia models provide a biochemical angle on DSIP that does not depend on EEG recordings (Khvatova et al., 2003). This work is often cited in discussions of the peptide as a stress-protective agent in animal models, a label that remains descriptive rather than mechanistic.

Stability and analog design

DSIP is cleaved rapidly in vitro by aminopeptidase-like enzymes that remove the N-terminal tryptophan. That instability led to modified analogs used to probe structure-activity relationships, and it complicates interpretation of in vivo work, because the intact peptide may persist only briefly (Kovalzon & Strekalova, 2006).

What the evidence does not show

The most important gap is basic: there is no known gene, precursor or receptor, so DSIP cannot yet be placed in a defined signaling system. Much of the literature dates from the 1970s to the 1990s, uses small groups of animals and older methods, and reports findings that other laboratories could not always reproduce. Effects on EEG differ between species and protocols. The rapid breakdown of the peptide raises questions about what reaches target tissue in any in vivo experiment. Reviewers have called DSIP “a still unresolved riddle” for these reasons (Kovalzon & Strekalova, 2006).

Regulatory status

Rogue Compounds sells this material as a research chemical, not for human use. It is sold for laboratory research only.

Handling and storage in the lab

Lyophilized DSIP should be kept sealed and refrigerated at 2–8°C (36–46°F), protected from light. The N-terminal tryptophan is light- and oxidation-sensitive, which is one more reason to keep the vial closed and shielded until use.

Sourcing and documentation

Rogue Compounds has DSIP made in small batches. Every vial carries a batch number and a QR code that opens the independent U.S. testing lab’s own report for that batch. The same batch COA is posted on the product page and in the COA Library.

View DSIP on Rogue Compounds

References

  1. Monnier M, et al. Experientia. 1977;33(4):548-552. PMID 862769
  2. Graf MV, Schoenenberger GA. J Neurochem. 1987;48(4):1252-1257. PMID 3029331
  3. Yehuda S, Carasso RL. Int J Neurosci. 1988;38(3-4):345-353. PMID 3286557
  4. Khvatova EM, et al. Peptides. 2003;24(2):307-311. PMID 12668217
  5. Kovalzon VM, Strekalova TV. J Neurochem. 2006;97(2):303-309. PMID 16539679

Research use only. Rogue Compounds products are sold strictly for laboratory research. They are not for human or veterinary use, and nothing in this article is medical advice. The studies cited here describe published research, not this product or any use of it.

Trust built by transparency. Scan the vial, read the lab’s own report.

Research peptides & laboratory compounds. Built by researchers. For researchers.

Support

Disclaimer

The statements provided herein have not been assessed by the Food and Drug Administration. These products are not designed to diagnose, treat, cure, or prevent any disease. Rogue Compounds does not operate as a compounding pharmacy or chemical compounding facility as defined under 503A/503B of the Federal Food, Drug, and Cosmetic Act. The products available on this website are intended for research use only and are not suitable for human or animal consumption.

© 2026 Rogue Compounds. All rights reserved.

For research use only